US equities |
MU $970.58 ▲+4.50% META $610.65 ▼-1.54% SPCX $144.22 ▼-2.94% TSLA $403.30 ▼-1.02% NVDA $217.01 ▼-0.42% SNDK $1,385.78 ▲+6.20% GOOGL $323.74 ▲+0.99% SKHY $164.21 ▲+12.97%
FinancialContent

West Pharmaceutical Services, Inc. Common Stock (NY:WST)

404.05 +5.76 (+1.45%)
Delayed Quote Updated: 2:30 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about West Pharmaceutical Services, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion ↗
The Microsoft founder's foundation recently added this healthcare stock to its portfolio. 
Via The Motley Fool
News headline image
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ:PACB) and i... 
Via StockStory
Topics Artificial Intelligence Economy
West Pharmaceutical Services (NYSE:WST) Shows Explosive Potential with Perfect Minervini Trend Template and Accelerating Growth ↗
Via Chartmill
News headline image
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Economy
West Pharmaceutical Services (NYSE:WST) Surges on Q1 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Azenta (NASDAQ:AZTA) a... 
Via StockStory
News headline image
1 S&P 500 Stock on Our Buy List and 2 Facing Headwinds
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Economy Stocks
News headline image
Drug Development Inputs & Services Stocks Q1 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laborato... 
Via StockStory
Topics Economy
News headline image
FDVV vs. NOBL: Which Dividend Stock ETF Is a Better Buy? ↗
A longer track record of dividends doesn't always equate to the best returns. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 We Find Risky
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
Topics Bonds Economy
News headline image
3 Healthcare Stocks We Steer Clear Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl... 
Via StockStory
Topics Economy
News headline image
The Top 5 Analyst Questions From West Pharmaceutical Services’s Q1 Earnings Call
West Pharmaceutical Services delivered a first quarter that exceeded Wall Street's expectations, driven by robust demand for its high-value product (HVP) com... 
Via StockStory
Topics Earnings
News headline image
1 Mooning Stock with Competitive Advantages and 2 Facing Headwinds
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
Topics Economy Retirement
News headline image
WST Q1 Deep Dive: High-Value Components and Operational Execution Drive Outperformance
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 21% year... 
Via StockStory
News headline image
3 Inflated Stocks with Open Questions
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne... 
Via StockStory
Topics Economy
These S&P500 stocks are moving in today's session ↗
Via Chartmill
Which S&P500 stocks have an unusual volume on Thursday? ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Thursday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
West (WST) Q1 2026 Earnings Call Transcript ↗
West (WST) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
These stocks are gapping in today's session ↗
Via Chartmill
Get insights into the top movers in the S&P500 index of Thursday's pre-market session. ↗
Via Chartmill
News headline image
West Pharmaceutical Services (NYSE:WST) Surprises With Strong Q1 CY2026, Stock Soars
Healthcare products company West Pharmaceutical Services (NYSE:WST) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 21% year on year to $... 
Via StockStory
Topics Economy
News headline image
Earnings To Watch: West Pharmaceutical Services (WST) Reports Q1 Results Tomorrow
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings this Thursday morning. Here’s what to expect. West Pharmaceuti... 
Via StockStory
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Economy
News headline image
1 Cash-Heavy Stock to Keep an Eye On and 2 That Underwhelm
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
Topics Economy
News headline image
3 High-Flying Stocks We Keep Off Our Radar
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta... 
Via StockStory
Topics Economy
News headline image
End of an Era: West Pharmaceutical Shares Slide as Longtime CEO Eric Green Announces Retirement
Shares of West Pharmaceutical Services (NYSE: WST) tumbled 5.7% on Tuesday following the announcement that Eric Green, the company’s President, Chief Executive Officer, and Chair of the Board, intends... 
Via MarketMinute
Topics Economy Retirement
News headline image
Winners And Losers Of Q4: West Pharmaceutical Services (NYSE:WST) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development ... 
Via StockStory
Topics Economy
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >